Introduction
An understanding of the natural history of disease is important for developing effective disease prevention and treatment programs. The objective of this paper is to consider the strengths and limitations of various epidemiologic study designs and sources of epidemiologic data for characterizing the natural history of disease.
A simple conceptual framework for the natural history of a disease is a two-stage model (Fig. 1 ). An individual is free of disease (healthy) until the onset of stage 1 disease. Stage 1 refers to preclinical or asymptomatic disease. It is assumed there is a diagnostic screening test that can detect the presence of stage 1 disease. The individual with stage 1 disease may eventually progress to stage 2, which is the clinical or symptomatic period. It is assumed that individuals enter stage 1 before the onset of stage 2 disease. The focus of this paper is on the natural history of disease up to the onset of symptomatic disease (stage 2).
Two types of covariates affect the natural history of disease. The first type, X1, are those that affect the risk of stage 1 disease. The hazard (or incidence) of onset of The second type of covariates, X12, are those that effect risk of progression to stage 2 from stage 1 disease. The duration of time spent in stage 1 has been termed the preclinical duration, the incubation period and the sojourn time (1) . The distribution function of stage 1 durations, F(t; X2), is the probability an individual with stage 1 disease progresses to stage 2 within t years of onset of stage 1. The corresponding hazard and density functions are called h(t; X2) and f(t; X2), respectively. The distribution function may be improper as not all individuals may eventually progress to stage 2. Two examples illustrate this conceptual framework: cervical cancer and the acquired immunodeficiency syndrome (AIDS). The (1) where g(s; IC,) = X(s; XI1)exp[ -X(s; Xl)ds] is the probability density of onset of stage 1 at time s. Eq. (1) has been used to project the course of the AIDS epidemic (7) (8) (9) . Inforrnation is available both on the numbers of AIDS cases diagnosed over calendar time and F(t) (the incubation period distribution). Thus estimates of the numbers of individuals previously infected can be obtained through the technique of back-calculation (8 In the next sections, we consider the strengths and limitations of alternative epidemiologic designs for characterizing the natural history of disease. We outline analytic approaches to estimate parameters that describe disease natural history. We assume in the next sections that the errors associated with the screening test are negligible and can be ignored, although in the last section, some consideration is given to situations in which screening test errors are not negligible.
The Cross-Sectional Study One of the simplest study designs is the cross-sectional study. Consider a large cohort of individuals defined at time s = 0. A random sample of these individuals is chosen at a point in time (s = Y). We test each individual in the sample for presence of stage 1 disease and obtain information on a covariate, Z. We assume, for simplicity, Z is dichotomous. A common practice is to cross classify individuals according to presence or absence of stage 1 disease and the two levels of the covariate (Z = 0 and Z = 1). This was the design of a recent study to investigate the relationship between HPV infection and early stages of cervical cancer (10) . What are the limitations of the cross-sectional study for characterizing natural history?
The most serious limitation is that the time sequence of events cannot be established. We cannot determine if an individual was exposed (Z = 1) before or after onset of stage 1 disease. This is an important limitation with cross-sectional studies of HPV infection and cervical cancer, because individuals with stage 1 (CIN) disease may be more (or perhaps less) prone to acquire HPV infection. This problem is not unique to the crosssectional study and occurs in the case-control study as well.
The issue of the time sequence does not arise if Z is a fixed covariate, that is, the value of the covariate is determined at time s = 0 for each individual. However, even if Z is a fixed covariate, the interpretation of commonly used parameters of association such as the odds ratio must be modified. Table 1 displays the classification probabilities associated with the.2 x 2 table which results from the crosssectional study, that is, the joint probability distribution of stage 1 disease (presence or absence) and the covariate value (Z = 0 or Z = 1). These probabilities depend on the following: the incidence of stage 1 disease, X(s; Z); the distribution of stage 1 durations, F(t; Z); the probability distribution of the covariate Z [i.e., P(Z = 1) = p and P(Z = 0) = 1 -p)]; and the time s = Y that the cross-sectional study is conducted. The odds ratio is the cross product of these cell probabilities, and is independent of p. Under the assumption that stage 1 disease is rare with constant incidence rate, that is Xl(s; Z) = exp(oto + a1Z), then the hazard XI(s; Z) is approximately the density of g(s; Z). The odds ratio from the cross-sectional study, WMC8 is approximately
If the study is conducted at a time s = Y sufficiently large so that then the term in brackets in Eq. (2) is nearly 1, then IC8--exp(ao (3) Under the above assumptions for which Eq. (3) (12) . More recent estimates based on cohorts of newly infected individuals suggest this cumulative probability is less than 0.05 (6,13).
Assuming a proportional hazards model h(t) = hO(t)exp(13Z) where t is the time since onset of stage 1 disease, then estimates of the relative risk exp(,B) derived from a prevalent cohort will be biased if the proportional hazards analysis is performed using follow-up time. There are two reasons for the bias. The first reason is that the distribution of the prior times of onset of stage 1 disease for two subgroups (Z = 0 and Z = 1) may be different (X(s; Z = 0) * X(s; Z = 1). For example, one prevalent cohort study reported a higher cumulative proportion of AIDS in New York than in Washington (12) . The most plausible explanation is the New York cohort was infected earlier in calendar time than the Washington cohort, and not that geography is a cofactor of disease progression. The second reason for bias occurs even if X(s; Z = 0) = X(s; Z = 1). This bias is due to the differential effects of length-biased sampling in the two subgroups (Z = 0 and Z = 1). The direction of the bias also depends on whether the hazard h(t) increases or decreases over time. For (4) Brookmeyer and Goedert describe this approach (14) . Modified Newton-Raphson algorithms can be used to find the maximum likelihood estimates of the parameters of the stage 1 and stage 2 disease incidence functions. The analysis produces not only estimates of relative risk of covariates but also estimates of the incubation period distribution, F(t; X2). The analysis (14) of the National Cancer Institute Multicenter Hemophilia Cohort Study found that age was a cofactor (X2) of disease progression. Table 2 gives the estimates of F(t) for hemophiliacs over the age of 20. The estimate of the 3-year cumulative probability of AIDS was only 0.033, which is considerably less than prior estimates obtained from prevalent cohorts.
Cohort Studies of Serially Screened Populations with Treatment Intervention
A major analytic complication of most cohort studies of disease natural history is that if an effective treat- 
Case-Control Studies of Serially Screened Populations with Treatment Intervention
There are a number of disadvantages of the cohort study described in the preceding section. If the disease is rare (X(s; IC) small) a very large cohort would be required and the screening program would have to be centrally organized. An alternative design is the casecontrol study. The advantage, of course, is follow-up on a large cohort is not required. However, an important limitation of the case-control design is that the absolute incidence of stage 1 is not estimable because the numbers of cases that are sampled are pre-fixed. Nevertheless, the case-control approach can be useful, and we briefly consider analytic approaches for gleaning information about natural history from matched case-control studies.
In case-control studies of a serially screened population, there are two types of cases. The conditional likelihood is independent of the parameters Xi, the baseline incidence of stage 1 disease in the ith matched set. This serves to emphasize again that it is not possible to estimate absolute incidence from a casecontrol study. A modification of this analytic approach was used in the analysis of a matched case-control study of PAP smear screening for cervical cancer in Northeast Scotland (17) . The modification accounted for screening test errors, and also accounted for the fact that not all preclinical lesions (stage 1 disease) progress to clinically (symptomatic) invasive cervical cancer (stage 2).
Errors in the Screening Test
We have considered the strengths, limitations, and analytic approaches associated with various epidemiologic designs for studies of disease natural history. An underlying assumption of the preceding sections was that diagnostic errors of the screening test were negligible and could be ignored. Often the test errors are not negligible; thus, the analytic approaches must be modified accordingly. There are two types of errors. The false positive error occurs when an individual without stage 1 disease falsely tests positive. The false negative error occurs when an individual with stage 1 disease falsely tests negative.
In order to develop analytic procedures in the presence of test errors, additional probabilistic assumptions are required. For example, one can assume the probability of a false positive error is 0, the probability of a false negative error is E, and further errors on successive screens are independent. These were the assumptions employed in an analysis of natural history from a breast cancer screening program (15) and a cervical cancer screening program (16) .
An alternative to the independence assumption is to assume a proportion of individuals with stage 1 disease always falsely test negative. Another alternative is to assume the probability of a false negative error changes over the course of stage 1 disease. For example, the preclinical stage (stage 1) of cervical cancer can be divided into a noninvasive preclinical disease phase and an invasive preclinical disease phase. One can assume that the false negative probabilities are different for the two phases and that test errors conditional of the disease state (i.e., precinical noninvasive or preclinical invasive) are independent.
Under model assumptions for test errors such as those described above, the likelihood function for the various epidemiologic designs could be derived. The likelihood function would include an additional parameter, E, which is the probability of false negative error. This parameter can be estimated jointly along with the other natural history parameters (1, 17) . However, an important caveat is that parameter estimates may be highly correlated. For example, under the independence assumption it was found that the estimate of e, the probability of a false negative error, and ,u, the mean stage 1 duration, were highly correlated (15) . Clearly, it would be preferable to use a reliable external estimate of E, if available, rather than to jointly estimate E along with the other natural history parameters.
However, even if an estimate of e was available, assumptions about the joint distribution of successive test results, conditional on the true disease state, would be required. An important issue in studies of disease natural history concerns the development of plausible assumptions about screening test errors and the sensitivity of estimates of natural history parameters to alternative model assumptions about these errors. R. Brookmeyer was partially supported by Public Health Service grants CA-48723 from the National Cancer Institute and AI-16959 from the National Institute of Allergy and Infections Diseases.
